Compare Robinhood Markets, Inc. (HOOD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Organon & Co. Common Stock — how do they compare? Robinhood Markets, Inc. trades at $98.28 (market cap $90.88B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Robinhood Markets, Inc. is far larger — about 25.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Organon & Co. Common Stock for 0 Days on average.
| HOOD | OGN | |
|---|---|---|
Market Cap | $90.88B | $3.61B |
Volume | 23,337,832 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $147.08 | $13.81 |
52-Week Low | $65.16 | $5.70 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $97.42B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $110.52, up 1.19% with a neutral technical signal. The company shows strong fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation metrics remain elevated (P/E 48.9, P/S 20.61). Recent news highlights expansion into 24/7 trading and AI-powered features, while earnings show mixed quarterly performance with two beats and one miss in the last four quarters.
Analyst consensus remains bullish with 74% buy ratings and a $138.60 price target, representing 25% upside potential. Key risks include high valuation multiples, competitive pressures in online brokerage, and regulatory scrutiny. The company's transformation into a broader financial services platform provides growth opportunities but requires careful execution.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
